Please assess the completion status of the following clinical trial:

Trial Title: Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a history of stable intermittent claudication lasting more than 6 months before Screening.~2. Has a diagnosis of peripheral arterial disease (PAD) (Code I70.2 according to the international classification of diseases-10th revision) Fontaine Stage IIB confirmed by ultrasound color duplex imaging.~3. Has a resting Doppler ankle-brachial index of less than or equal to (\<=) 0.9.~4. Has intermittent claudication with initial claudication distance (ICD) less than (\<) 200 meters.~5. Is not newly diagnosed with PAD and has a history of stable PAD therapy for at least 2 weeks before Screening.~Exclusion Criteria:~1. Has PAD Fontaine Stage III or IV (pain at rest, non-healing ulceration, or gangrene).~2. Has evidence of nonatherosclerotic PAD.~3. Has greater than (\>) 25 percent (%) variability in absolute claudication distance (ACD) based on treadmill testing during the screening period.~4. Has lower extremity arterial reconstruction (surgical or endovascular) or sympathectomy within 3 months before Screening.~5. Is eligible for surgical/interventional reconstruction.~6. Had a myocardial infarction or major cardiac surgery within 3 months before Screening.~7. Has congestive heart failure (New York Heart Association Class III/IV).~8. Has uncontrolled diabetes mellitus (glycosylated hemoglobin \[HbA1c \>9%\]) or diabetic polyneuropathy.~9. Has any other illness that significantly limits exercise capacity or other medical condition, including any psychiatric disorder that limits participation (in the judgement of the investigator).~10. The subject has received any prohibited medication within 14 days before Randomization (Day 1)~11. The subject is undergoing the supervised exercise training program by the time of Screening and is going to continue this program due to its effectiveness.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Actovegin 1200 mg (Type: EXPERIMENTAL): Actovegin 1200 milligram (mg), intravenously, once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Actovegin placebo-matching, intravenously, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).